In the last cpl days, there has been news items re: TALON preparing to be sold. The price (on the low end) would be very nice for us... Can't post a link anymore on here - just Google it - but here's a portion pasted:
TLON takeover 300-400M possible - Dealreporter story!
Talon Therapeutics (OTC BB:TLON) has engaged Goldman Sachs for a sale process, said two industry bankers claiming knowledge.
The company expects to wrap up the process of evaluating the inbound inquiries in two to six months, Carlson said.
While Talon explores its options, it also is moving ahead with plans to commercialize Marqibo on its own, Carlson also said. The company expects it can launch the drug in the first quarter of next year on its own, if it does not strike a takeout deal or partnership, according to CEO Steven Deitcher and Carlson.
The drug is a treatment for adult patients with Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies. Studies are currently in progress for expanding the drug’s label in other hematology and cancer indications, according to the company.
The indication for the drug is currently limited, and a lot of the value assigned to the potential sale price will be driven by how easily bidders think the indication for the drug can be expanded, said the banker. Should bidders have confidence the label can be expended, Celgene could be a bidder for Talon, said the person familiar. If not, Spectrum Pharmaceuticals could attempt to buy Talon alone for the single indication, added the person familiar. Spectrum, however, only paid USD 108m to purchase Allos Therapeutics, which recently had launched Flotyn